Improving tolerability of immunosuppressive regimens

Transplantation

Volumn 72, Issue 12 SUPPL., 2001, Pages

  MacDonald, A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG MECHANISM; GLUCOSE INTOLERANCE; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; NEPHROTOXICITY; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0035678342     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofefil after cadaveric kidney transplantation
2. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients
3. FK 506 and mycophenolate mofefil in renal transplant recipients: Six-month results of a multicenter, randomized dose ranging trial
4. Strategies to reduce or replace steroid dosing
5. Corticosteroids in kidney transplant recipients: Safety issues and timing of discontinuation
6. Improved cadaveric renal transplant outcome in children
7. Incidence and long-term cost of steroid-related side effects after renal transplantation
8. Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
9. Mechanisms of nephrotoxicity
10. Impact and management of hyperlipidemia posttransplantation
11. Impact and management of posttransplant diabetes mellitus
12. Management strategies for posttransplant hypertension
13. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol
14. Gingival enlargement induced by drugs
15. Two cases of tacrolimus-induced alopecia following kidney transplantation
16. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
17. Neurotoxicity of calcineurin inhibitors: Impact and clinical management
18. Causes of graft loss beyond two years in the cyclosporine era
19. Factors affecting compliance with cyclosporine in adult renal transplant patients
20. The impact of first-line antihypertensive drugs on erectile dysfunction
21. What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy
22. Review of controlled trials of Gabitril (tiagabine): A clinician's viewpoint
23. Basic mechanisms of Gabitril (tiagabine) and future potential developments
24. Immunophilins: Beyond immunosuppression
25. Molecular mechanisms of the immunosuppressive action of cyclosporin A
26. Immunopharmacology of rapamycin
27. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
28. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
29. Mechanism of action of the immunosuppressant rapamycin
30. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability
31. A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation
32. Interleukin-2-mediated elimination of the p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin
33. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
34. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey
35. Synergistic effect of rapamycin and cyclosporine in prevention of acute kidney allograft rejection in the mouse
36. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection
37. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat
38. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival
39. Management of deep venous thrombosis and pulmonary embolism
40. DVT treatment in 2000: State of the art
41. Synergistic effects of mycophenolate mofetil and siroiimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat
42. Vascular and cellular mechanisms of chronic renal allograft dysfunction
43. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates
44. Is nonnephrotoxic immunosuppression a possibility?
45. Cancer cell cycle control
46. Genetic instability as a consequence of inappropriate entry into and progression through S-phase
47. s6K pathway in human pancreatic cancer cells
48. s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells
49. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells
50. Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation
51. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts
52. A direct linkage between the phosphoinostide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells
53. Kipl and its alterations in tumor cells: A review
54. Regulation of the Cdk inhibitor p27 and its dysregulation in cancer
55. Translation factors as effectors of cell growth and tumorigenesis
56. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A Phase II trial
57. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
58. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
59. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
60. Acute effects of rapamycin on glomerular dynamics: A micropuncture study in the rat
61. The effect of rapamycin on kidney function in the Sprague-Dawley rat
62. A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients
63. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
64. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
65. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
66. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
67. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent
68. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: Evidence for pharmacokinetic interactions
69. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
70. Management strategies for nephrotoxicity
71. Toxicity and efficacy of sirolimus: Relationship to whole-blood concentrations
72. Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience
73. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus